Výsledky vyhledávání

A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms

Autor: Rose Fida, Terra L. Lasho, Animesh Pardanani, Ayalew Tefferi, Gregg Smith, Kebede H. Begna, Geeta George, William J. Hogan, Mark R. Litzow, Curtis A. Hanson, Christopher J. Burns

Publikováno v: Blood. 116:460-460

Abstract 460 Background: CYT387 is a potent JAK-1/2 inhibitor that suppresses the in vitro growth of cells harboring JAK2V617F (Leukemia 2009;23:1441) and was effective in a murine model of myeloproliferative neoplasms (MPN) (Blood 2010;115:5232). Ai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a62751852bfd12cfd010852523a78f2
https://doi.org/10.1182/blood.v116.21.460.460

Zobrazit plný text záznamu

Abstract A16: Antitumor activity of CYT997: A phase II vascular disrupting agent administered orally in combination with cisplatin in a colon adenocarcinoma xenograft model

Autor: Christopher J. Burns, Stuart Nelson, Andrew K. Powell, Gregg Smith, Rose Fida, Steven D. Shnyder, Patricia A. Cooper

Publikováno v: Molecular Cancer Therapeutics. 8:A16-A16

CYT997 is an orally bioavailable small molecule vascular-disrupting agent (VDA) that is currently being investigated in Phase II clinical studies. In vitro efficacy studies have demonstrated that CYT997 exhibits potent antiproliferative activity agai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f4607cedf7dff362e6c0acc0e1c3b58c
https://doi.org/10.1158/1535-7163.targ-09-a16

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání